The global antiviral drugs market is predicted to grow to USD 48.18 billion by 2028 from USD 37.48 billion in 2023. This market is forecasted to grow at a CAGR of 5.15% during the forecast period.
Antiviral drugs are described as curative or disease-controlling agents against viral infections. These drugs individually attack viruses at different metabolic processes and alter the normal functioning of viral particles. However, over the past few years, resistance has been observed among viruses against different antiviral drugs with an increasing diversity of microorganisms. This challenge led to the evolution of broad-spectrum antiviral medicines that attack viruses at specified targets, such as DNA Polymerase, NS3 Protease, & Reverse Transcriptase. These drugs prevent or cure viral infections such as HIV/AIDS, Hepatitis, influenza, and other infections.
Anti-virus drugs are a class of medicine that kills a virus such as HIV, chickenpox, papilloma, hepatitis B and C viruses, herpes viruses, influenza A and b viruses, or suppress the virus's ability to replicate. Most anti-viruses target specific types of viruses. Moreover, a broad-spectrum anti-virus drug is effective against an extensive range of viruses. On the other hand, the unlanti-viral number of antibiotics and antiviral drugs do not kill their target pathogen. The global antiviral drug market showed consistent growth in the pharmaceutical industry and is predicted to continue the growing trend in the coming years due to the rise in awareness in the people and better efficiency of the developed drug. The significant patents in anti-virus drugs are Tenofovir, Tamiflu, Relenza, Telbivudine, and Sustivahave changed the anti-virus face.
Y-O-Y's growth in the incidence of viral infections is majorly accelerating the growth of the global antiviral drugs market.
The global antiviral drugs market is primarily driven by infections such as influenza, respiratory syncytial virus, hepatitis, and HIV. An increase in research and development activities and innovation of new formulations, including vaccines and various therapy, is anticipated to drive the market's growth. According to the report of UNAIDS, there were 37.9 million people globally who had HIV/AIDS in 2019. Of that, 36.2 million people were adults, 1.7 million were children, and 770000 died from this disease.
Additionally, growing public awareness, a boost in the R &D segment, increasing interest to support the development of novel antiviral drugs, and a well-established supply chain further lavish the growth of the global antiviral drugs market.
Furthermore, the rise in healthcare infrastructure spending capability in developed and developing countries, increasing dilation of life-threatening virus disease, and people awareness fuel market growth. As late-stage pipeline drugs are anticipated to hit the market, this further supports the antiviral drugs market growth.
The high cost involved in developing drugs and increased demand for different medicine like naturopathy and homeopathy-viral is degrading the market growth of antiviral medication. In addition to this high risk of failure, the high cost of research and therapy and stringent government activities hamper the market's growth. Therefore, increasing the use of natural products is the market's critical challenge.
Furthermore, increasing preventive measures and the availability of vaccines for various viral diseases hamper the antiviral drugs market growth to some extent.
Impact of COVID-19 on the global antiviral drugs market:
Millions of people across the world are affected by the coronavirus. This pandemic has put massive pressure on medicine safety stocks. Healthcare providers such as doctors and nurses use every possible tool to treat COVID-19 and other related infections. It results in tremendous pressure on several medicines, including antiviral drugs. Similarly, the pressure on the system is substantially growing with increased demand from patients and governments for crucial medicines. Scientists and researchers are relentlessly working to develop an investigational antiviral compound to treat the SARS-CoV-2 virus.
Antiviral composites show activity against SARS-CoV-2 in preclinical Screenings. The companies are collaborating (ex: Pfizer and BioNTech) to develop the COVID-19 vaccine due to the rising demand. The companies predicted the lead COVID-19 vaccine selection in January 2020; they are expected to form the lead vaccine by September 2020. The first batch of the COVID-19 vaccine could be available for emergency use approval in early 2021. In addition, many huge companies are expanding their global manufacturing capacity. So, the additional capacity will contribute to the fast production of the antiviral vaccine, and they can supply more than one billion doses of an effective vaccine globally.
Recently, companies have brought affordable vaccines for the public of the vast demand, not for profit but for emergency pandemic use. These drugs will give potential immunity to the patients. Governments are giving approvals for the fast scale-up; it can also help them reopen economies. Still, there are no potential treatments and vaccines for Covid-19; major companies are trying to use existing drugs to fight against the novel coronavirus. The use of specific antiviral drugs for Covid-19 treatment contributes to the growth of the global antiviral drugs market. Moreover, any of these drugs under trial express promising results in treating the Covid-19 infection.
Market Size Available
2022 to 2028
2023 to 2028
By Application, Target, End Users, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
This research report on the global antiviral drugs market is segmented and sub-segmented based on the application, target, end-users, and region.
Antiviral Drugs Market - By Application:
Based on application, the HIV/AIDS and the Hepatitis segments accounted for the highest market share in the global antiviral drugs market in 2022 and are predicted to continue their domination throughout the forecast period. The growth is primarily driven due to the standard increase of transmitted infectious diseases.
Antiviral Drugs Market - By Target:
Based on the target, the reverse transcriptase segment is projected to perform well during the forecast period. Therefore, this segment will influence the antiviral drugs market in the forthcoming years due to its efficacy in averting or slowing down viral infections.
Antiviral Drugs Market - By End Users:
Based on the End-User, the hospital's segment was accounted for the largest share in 2022 and forecasted to grow at the highest CAGR during the forecast period. The segment's growth is attributed to many patients and their admissions, which are responsible for the growth of the antiviral drugs market.
Antiviral Drugs Market - By Region:
The Middle East and Africa
Regionally, the North American antiviral drugs market is forecasted to be the most influencing region in the global antiviral drugs market and will account for more than 34.0% of the global market share in 2021. The factors responsible for the market's growth in this region include an emergency of the critical situation of diseases and a standard increase of infectious diseases across the globe. In this region, the United States is the leading market.
The Europe market stands second in leading highest shares in the global antiviral drugs market, followed by North America. The European antiviral drugs market size is projected to grow at a CAGR value of 4.98% over the forecast period. Factors such as new vaccines coming into the market by the key players and common infectious diseases fuel market growth. The UK leads the market in this region.
The Asia-Pacific market is expected to grow fast, with a CAGR value of 6.12% from 2021 to 2026. China is the most lucrative country in the Asia Pacific antiviral drugs market, obtaining majority shares in the market in 2019 due to increasing knowledge in public and the launch of new products. Japan is next to China in showcasing a healthy CAGR.
The Latin American antiviral drugs market size is estimated to be worth USD 5.06 billion by 2025. In addition, the governments of the Latin America region are working on introducing new antiviral drugs for those who are suffering from infectious diseases like Hepatitis C, also HIV/AIDS. These factors are responsible for market growth in Latin America.
The Middle East & Africa region is estimated to showcase a CAGR of 5.07% during the forecast period. Factors such as increased healthcare expenditure, rising occurrence of viral infections, and utilization of natural medicines are majorly propelling the market growth in this region.
KEY MARKET PARTICIPANTS:
Companies leading the global antiviral drugs market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Roche Holding AG (Switzerland), Pfizer (USA), Merck and Co. Inc. (USA), GlaxoSmithKline plc (United Kingdom), AstraZeneca AB (United Kingdom), Gilead Sciences (USA) and Abbott Laboratories (USA).
As per our research report, the global antiviral drugs market is valued at USD 48.18 billion in 2028.
The size of the global antiviral drugs market is projected to grow at a CAGR of 5.15% during the forecast period 2023 to 2028.
North America region is accounted for the largest market share during the forecast period 2023 to 2028.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org